AAN 2024: Myostatin inhibitors on the horizon for the treatment of SMA

At the American Academy of Neurology (AAN) 2024 Annual Meeting, Biohaven presented its Phase III RESILIENT trial (NCT05337553), which investigates the efficacy and safety of taldefgrobep alfa in patients with spinal muscular atrophy (SMA).